Xilio Therapeutics (XLO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.55, -5.21% vs the prior close of $9.02.
- Volume 29.43K shares, 2.7x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
XLO slides 5.2% to $8.55, a 1-month low on 2.7x normal volume. Closed at $8.55, -5.21% vs the prior close of $9.02. Day range $8.55–$9.00, opened at $8.91.
XLO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — XLO slides 5.2% to $8.55, a 1-month low on 2.7x normal volume
- Closed at $8.55, -5.21% vs the prior close of $9.02. Day range $8.55–$9.00, opened at $8.91.
- Volume was 29.43K shares, 2.7x its 50-day average of 10.75K — unusually heavy trading.
- Price is -5.5% vs its 50-day average ($9.05) and -0.2% vs its 200-day average ($8.57).
- 52-week range $6.47–$12.59; today's close sits at 34% of that range, 32.1% below the 52-week high.
Oct 15, 2026 — XLO rises 1.3% to $9.02
- Closed at $9.02, +1.35% vs the prior close of $8.90. Day range $8.88–$9.38, opened at $8.88.
- Volume was 10.40K shares, 1.0x its 50-day average of 10.66K.
- Price is -0.5% vs its 50-day average ($9.06) and +5.2% vs its 200-day average ($8.57).
- 52-week range $6.47–$12.59; today's close sits at 42% of that range, 28.3% below the 52-week high.
Oct 14, 2026 — XLO slides 3.5% to $8.90, a 1-month low
- Closed at $8.90, -3.47% vs the prior close of $9.22. Day range $8.77–$9.08, opened at $9.08.
- Volume was 12.40K shares, 1.1x its 50-day average of 10.82K.
- Price is -1.8% vs its 50-day average ($9.07) and +3.8% vs its 200-day average ($8.57).
- 52-week range $6.47–$12.59; today's close sits at 40% of that range, 29.3% below the 52-week high.
Oct 13, 2026 — XLO rises 1.6% to $9.22, a 1-month high, 3 up days in a row
- Closed at $9.22, +1.60% vs the prior close of $9.07. Day range $8.85–$9.22, opened at $9.05.
- Volume was 18.10K shares, 1.7x its 50-day average of 10.84K.
- Price is +1.7% vs its 50-day average ($9.07) and +7.5% vs its 200-day average ($8.57).
- 52-week range $6.47–$12.59; today's close sits at 45% of that range, 26.7% below the 52-week high.
- That makes 3 straight gains.
Oct 12, 2026 — XLO ends flat (+0.3%) to $9.07
- Closed at $9.07, +0.28% vs the prior close of $9.05. Day range $8.98–$9.42, opened at $9.11.
- Volume was 8.40K shares, 0.8x its 50-day average of 10.90K.
- Price is +0.1% vs its 50-day average ($9.07) and +5.9% vs its 200-day average ($8.57).
- 52-week range $6.47–$12.59; today's close sits at 43% of that range, 27.9% below the 52-week high.
Oct 9, 2026 — XLO rises 0.4% to $9.05
- Closed at $9.05, +0.44% vs the prior close of $9.01. Day range $8.82–$9.16, opened at $8.94.
- Volume was 5.50K shares, 0.5x its 50-day average of 10.89K — lighter than usual.
- Price is -0.2% vs its 50-day average ($9.07) and +5.5% vs its 200-day average ($8.57).
- 52-week range $6.47–$12.59; today's close sits at 42% of that range, 28.1% below the 52-week high.
Oct 8, 2026 — XLO ends flat (+0.0%) to $9.01 on 1.9x normal volume
- Closed at $9.01, +0.00% vs the prior close of $9.01. Day range $8.77–$9.14, opened at $9.01.
- Volume was 20.80K shares, 1.9x its 50-day average of 10.71K — unusually heavy trading.
- Price is -0.6% vs its 50-day average ($9.07) and +5.1% vs its 200-day average ($8.58).
- 52-week range $6.47–$12.59; today's close sits at 42% of that range, 28.4% below the 52-week high.
Oct 7, 2026 — XLO ends flat (+0.1%) to $9.01
- Closed at $9.01, +0.11% vs the prior close of $9.00. Day range $9.00–$9.01, opened at $9.00.
- Volume was 900 shares, 0.1x its 50-day average of 11.65K — lighter than usual.
- Price is -0.6% vs its 50-day average ($9.07) and +5.0% vs its 200-day average ($8.58).
- 52-week range $6.47–$12.59; today's close sits at 42% of that range, 28.4% below the 52-week high.
Oct 6, 2026 — XLO dips 1.2% to $9.00
- Closed at $9.00, -1.21% vs the prior close of $9.11. Day range $8.81–$9.32, opened at $9.10.
- Volume was 6.20K shares, 0.5x its 50-day average of 12.28K — lighter than usual.
- Price is -0.8% vs its 50-day average ($9.07) and +4.9% vs its 200-day average ($8.58).
- 52-week range $6.47–$12.59; today's close sits at 41% of that range, 28.5% below the 52-week high.
Oct 5, 2026 — XLO rises 1.1% to $9.11
- Closed at $9.11, +1.11% vs the prior close of $9.01. Day range $9.07–$9.49, opened at $9.07.
- Volume was 7.20K shares, 0.6x its 50-day average of 12.54K — lighter than usual.
- Price is +0.4% vs its 50-day average ($9.07) and +6.2% vs its 200-day average ($8.58).
- 52-week range $6.47–$12.59; today's close sits at 43% of that range, 27.6% below the 52-week high.
Oct 2, 2026 — XLO rises 1.1% to $9.01
- Closed at $9.01, +1.12% vs the prior close of $8.91. Day range $8.89–$9.07, opened at $8.89.
- Volume was 7.40K shares, 0.6x its 50-day average of 13.42K — lighter than usual.
- Price is -0.6% vs its 50-day average ($9.06) and +5.0% vs its 200-day average ($8.58).
- 52-week range $6.47–$12.59; today's close sits at 42% of that range, 28.4% below the 52-week high.
XLO latest news & SEC filings
Every SEC filing by or about XLO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $18.69M (prior year $8.08M) (+131.2% vs Jun 30, 2025)
- Net income: -$6.37M (prior year -$15.84M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.33 (prior year -$2.30) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade XLO
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 23, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.18% (largest 5.2%).
- Liquidity: about 9.70K shares (≈$82.90K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $8.55 vs a range of $6.47–$12.59 (34% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:14 on Mar 16, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 8 sales; latest: James Samuel Shannon bought 5,000 shares on Mar 26, 2026.
- Latest filings: 10-Q Aug 12, 2026; 8-K Aug 12, 2026; 8-K Jun 12, 2026.
- Share count: 5.78M shares outstanding (Mar 18, 2026), -88.8% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
XLO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 8.91 | 9.00 | 8.55 | 8.55 | 29.43K |
| Oct 15, 2026 | 8.88 | 9.38 | 8.88 | 9.02 | 10.40K |
| Oct 14, 2026 | 9.08 | 9.08 | 8.77 | 8.90 | 12.40K |
| Oct 13, 2026 | 9.05 | 9.22 | 8.85 | 9.22 | 18.10K |
| Oct 12, 2026 | 9.11 | 9.42 | 8.98 | 9.07 | 8.40K |
| Oct 9, 2026 | 8.94 | 9.16 | 8.82 | 9.05 | 5.50K |
| Oct 8, 2026 | 9.01 | 9.14 | 8.77 | 9.01 | 20.80K |
| Oct 7, 2026 | 9.00 | 9.01 | 9.00 | 9.01 | 900 |
| Oct 6, 2026 | 9.10 | 9.32 | 8.81 | 9.00 | 6.20K |
| Oct 5, 2026 | 9.07 | 9.49 | 9.07 | 9.11 | 7.20K |
| Oct 2, 2026 | 8.89 | 9.07 | 8.89 | 9.01 | 7.40K |
| Oct 1, 2026 | 8.97 | 9.12 | 8.79 | 8.91 | 12.90K |
| Sep 30, 2026 | 9.19 | 9.25 | 9.05 | 9.05 | 5.40K |
| Sep 29, 2026 | 9.57 | 9.57 | 8.94 | 8.94 | 3.10K |
| Sep 28, 2026 | 9.21 | 9.22 | 8.96 | 9.05 | 11.10K |
| Sep 25, 2026 | 9.00 | 9.21 | 8.93 | 9.04 | 3.40K |
| Sep 24, 2026 | 8.93 | 9.09 | 8.93 | 9.00 | 16.00K |
| Sep 23, 2026 | 9.03 | 9.04 | 8.94 | 8.94 | 1.30K |
| Sep 22, 2026 | 9.04 | 9.16 | 8.95 | 9.04 | 6.90K |
| Sep 21, 2026 | 8.96 | 9.18 | 8.96 | 9.02 | 7.10K |
About Xilio Therapeutics
Xilio Therapeutics (XLO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1840233.
XLO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Akintunde Olatokumbo Bello | Director | Jun 12, 2026 |
| Cheryl R Blanchard | Director | Apr 16, 2026 |
| Sara Bonstein | Director | Jun 12, 2026 |
| Aoife Brennan | Director | Jun 12, 2026 |
| Daniel J. Curran | Director | Jun 12, 2026 |
| Robert W. Ross | Director | Jun 12, 2026 |
| Rene Russo | PRESIDENT AND CEO | Jan 5, 2026 |
| James Samuel Shannon | Director | Jun 12, 2026 |
| Yuan Xu | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Jan 5, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | Jan 5, 2026 |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | Jan 5, 2026 |
| Rene Russo | PRESIDENT AND CEO | Jan 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 26, 2026 | James Samuel Shannon | Buy | 5,000 | $8.79 |
| Mar 26, 2026 | James Samuel Shannon | Buy | 5,000 | $8.79 |
| Mar 26, 2026 | James Samuel Shannon | Buy | 5,000 | $8.79 |
| Mar 26, 2026 | James Samuel Shannon | Buy | 5,000 | $8.79 |
| Jan 2, 2026 | Christopher James Frankenfield | Sale | 7,030 | $0.64 |
| Jan 2, 2026 | Christopher James Frankenfield | Sale | 7,030 | $0.64 |
| Jan 2, 2026 | Christopher James Frankenfield | Sale | 7,030 | $0.64 |
| Jan 2, 2026 | Christopher James Frankenfield | Sale | 7,030 | $0.64 |
| Jan 2, 2026 | Kevin M. Brennan | Sale | 1,826 | $0.64 |
| Jan 2, 2026 | Kevin M. Brennan | Sale | 1,826 | $0.64 |
| Jan 2, 2026 | Kevin M. Brennan | Sale | 1,826 | $0.64 |
| Jan 2, 2026 | Kevin M. Brennan | Sale | 1,826 | $0.64 |
XLO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $43.77M | $-35.04M | -4.19 | $-4.99M |
| Dec 31, 2024 | $6.34M | $-58.24M | -15.24 | $-18.38M |
| Dec 31, 2023 | — | $-76.40M | -2.78 | $-68.62M |
| Dec 31, 2022 | — | $-88.22M | -3.22 | $-75.72M |
| Dec 31, 2021 | — | $-75.80M | -13.52 | $-80.75M |
Latest balance sheet: total assets $154.25M, total liabilities $81.99M, cash $136.04M (as of Jun 30, 2026).
XLO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $9.05 |
| May 12, 2026 | 8-K Item 2.02 (results) | $7.73 |
| Mar 23, 2026 | 8-K Item 2.02 (results) | $7.86 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $10.14 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $9.83 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $9.84 |
| May 8, 2025 | 8-K Item 2.02 (results) | $10.08 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $11.10 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $14.56 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Apr 1, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on XLO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.